
').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Topics
Glenmark Pharmaceuticals | USFDA | Pharma Companies

').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Glenmark Pharmaceuticals on Wednesday said it has received approval from the US health regulator to market Sodium Phenylbutyrate tablets, used in treating urea cycle disorders, in America.
The company has received final approval from the US Food and Drug Administration (USFDA) for the product which is a generic version of Horizon Therapeutics' Buphenyl, the Mumbai-based drug maker said in a statement.
According to IQVIA sales data for 12-month period ended September 2022, Buphenyl had annual sales of around USD 8.7 million.
Glenmark's current portfolio consists of 177 products authorised for distribution in the US marketplace and 46 abbreviated new drug applications (ANDAs) pending approval with the USFDA.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
First Published: Wed, November 02 2022. 13:48 IST
ClearBank has spent much of the past decade building the technology and regulatory infrastructure needed to challenge so... Read more
ClearBank’s progress shows that modern clearing and banking infrastructure can become a sizeable and profitable busine... Read more
There is something quietly symbolic about JPMorgan Chase choosing Berlin as its gateway into continental Europe. In a fo... Read more
There is a moment in every bull run when the narrative starts to fray. Not with a crash, not with a scandal, but with so... Read more
Coutts steps into private marketsCoutts, the private bank best known for serving Britain’s wealthiest families and the... Read more
How Crypto Moved from the Wild West to the Mainstream Financial SystemA long-form analysis of Bitcoin's journey from fri... Read more